NO20084007L - Spirokondenserte piperidiner som modulatorer av muskarinreseptorer - Google Patents

Spirokondenserte piperidiner som modulatorer av muskarinreseptorer

Info

Publication number
NO20084007L
NO20084007L NO20084007A NO20084007A NO20084007L NO 20084007 L NO20084007 L NO 20084007L NO 20084007 A NO20084007 A NO 20084007A NO 20084007 A NO20084007 A NO 20084007A NO 20084007 L NO20084007 L NO 20084007L
Authority
NO
Norway
Prior art keywords
modulators
spirocondensed
piperidines
muscarinic receptors
present
Prior art date
Application number
NO20084007A
Other languages
English (en)
Norwegian (no)
Inventor
Lewis R Makings
Miguel Garcia-Guzman Blanco
Akiko Nakatani
Ioana Drutu
Daniele M Bergeron
Andreas P Termin
Gabriel Raffai
Alina Silina
Dennis J Hurley
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20084007L publication Critical patent/NO20084007L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
NO20084007A 2006-02-22 2008-09-19 Spirokondenserte piperidiner som modulatorer av muskarinreseptorer NO20084007L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77552406P 2006-02-22 2006-02-22
US77550106P 2006-02-22 2006-02-22
PCT/US2007/004745 WO2007100670A1 (en) 2006-02-22 2007-02-22 Spiro condensed piperidnes as modulators of muscarinic receptors

Publications (1)

Publication Number Publication Date
NO20084007L true NO20084007L (no) 2008-10-07

Family

ID=38222350

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084007A NO20084007L (no) 2006-02-22 2008-09-19 Spirokondenserte piperidiner som modulatorer av muskarinreseptorer

Country Status (12)

Country Link
US (1) US8263605B2 (de)
EP (1) EP1987034B1 (de)
JP (1) JP2009527569A (de)
KR (1) KR20080098070A (de)
AT (1) ATE517106T1 (de)
AU (1) AU2007221220A1 (de)
CA (1) CA2642649A1 (de)
IL (1) IL193479A0 (de)
NO (1) NO20084007L (de)
NZ (1) NZ570497A (de)
RU (1) RU2008137583A (de)
WO (1) WO2007100670A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780015B1 (de) 2011-11-18 2017-01-04 Heptares Therapeutics Limited M1 muskarinrezeptoragonisten
SG11201606269WA (en) 2014-02-06 2016-09-29 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
AU2018352828A1 (en) 2017-10-17 2020-04-23 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
WO2019126559A1 (en) * 2017-12-20 2019-06-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
JP7644009B2 (ja) 2018-12-21 2025-03-11 オゲダ エス.エー. 3-メチル-1,2,4-チアジアゾール-5-カルボヒドラジドまたはそのメチル-d3重水素化形態の合成
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
EP4061813B1 (de) * 2019-11-22 2025-06-04 F. Hoffmann-La Roche AG Pyrrolidinderivate

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666764A (en) 1970-08-26 1972-05-30 Mead Johnson & Co Spiroindenylpiperidines
US3654287A (en) 1970-08-26 1972-04-04 Mead Johnson & Co Spiroindanylpiperidines
US3959475A (en) 1973-12-12 1976-05-25 American Hoechst Corporation Substituted 1,3-dihydrospiro(isobenzofuran)s
US3962259A (en) 1973-12-12 1976-06-08 American Hoechst Corporation 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof
JPS54109983A (en) 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
GB1575800A (en) 1978-05-16 1980-10-01 Sumitomo Chemical Co Spiro amines their production and compositions containing them
US4349549A (en) 1981-05-18 1982-09-14 Syntex (U.S.A.) Inc. Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s
JPS5815979A (ja) 1981-07-11 1983-01-29 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体およびその製造法
JPS5959685A (ja) 1982-09-28 1984-04-05 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
GB2131021B (en) 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
US4558049A (en) 1982-11-24 1985-12-10 Farmitalia Carlo Erba S.P.A. Antipsycotic benzoxazines
SE445649B (sv) 1983-06-08 1986-07-07 Jorgen Hermansson Anvendning av en fast berare med immobiliserad orosomucoid for separation, forfarande for framstellning av separationsmaterial, separationsanordning samt separationsmaterial
GB8917069D0 (en) 1989-07-26 1989-09-13 Merck Sharp & Dohme Therapeutic agents
CA2037357A1 (en) 1990-03-02 1991-09-03 Ben E. Evans Methods for using spirocyclic oxytocin antagonists
US5091387A (en) 1990-03-02 1992-02-25 Merck & Co., Inc. Spirocyclic oxytocin antagonists
EP0445974A3 (en) 1990-03-05 1992-04-29 Merck Sharp & Dohme Ltd. Spirocyclic antipsychotic agents
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
EP0533243B1 (de) 1991-09-16 1997-12-17 Merck & Co. Inc. Hydantoin und Succinimid-substituierte Spiroindanylcamphorsulfonyl als Oxytocin-Antagonisten
DK78692D0 (da) 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
WO1994013696A1 (en) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5457207A (en) 1993-10-05 1995-10-10 Regents Of The University Of Minnesota Spirovesamicols
HUT75224A (en) 1993-10-19 1997-04-28 Merck & Co Inc Combination of bisphosphonates and growth hormone secretagogues
WO1995014025A1 (en) 1993-11-16 1995-05-26 Merck & Co., Inc. Piperidinylcamphorsulfonyl oxytocin antagonists
WO1995028389A1 (en) 1994-04-15 1995-10-26 Yamanouchi Pharmaceutical Co., Ltd. Spiro compound and medicinal composition thereof
GB9417956D0 (en) * 1994-09-02 1994-10-26 Merck Sharp & Dohme Therapeutic agents
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5627196A (en) 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
US6130217A (en) 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
GB2308064A (en) 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
WO1997041878A1 (en) 1996-05-07 1997-11-13 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
EP0900086A4 (de) 1996-05-07 2000-01-12 Merck & Co Inc Verbesserung des schlafs mittels eines die sekretion von wachstumshormonen fördernden stoffes
FR2755133B1 (fr) * 1996-10-31 1999-01-15 Sanofi Sa Nouveaux derives d'amides cycliques diversement substitues antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
BR9812118A (pt) 1997-07-31 2000-07-18 Elan Pharm Inc Compostos do tipo 4-amino-fenilalanina que inibem adesão de leucócito mediada por vla-4
EP1009405A4 (de) * 1997-08-28 2001-05-09 Merck & Co Inc Payrrolidine und piperidine modulatoren der chemokine rezeptoraktivitaet
US6013652A (en) 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
GB9810886D0 (en) 1998-05-13 1998-07-22 Lilly Industries Ltd Pharmaceutical compounds
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
JP2002521436A (ja) 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション 置換アニリド化合物および方法
CA2338804A1 (en) 1998-07-28 2000-02-10 Smithkline Beecham Corporation Propenamides as ccr5 modulators
WO2000038720A1 (en) 1998-12-24 2000-07-06 Meiji Seika Kaisha, Ltd. Remedies for pain
AU3386700A (en) * 1999-03-02 2000-09-21 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
ITMI991452A1 (it) 1999-07-01 2001-01-01 Mediolanum Farmaceutici Srl Antagonisti selettivi per i recettori m2 con struttura 5h-dibenzo b,fazepinica
US6803372B2 (en) 1999-08-20 2004-10-12 Banyu Pharmaceutical Co., Ltd. Spiro compounds
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
AU7716600A (en) 1999-09-30 2001-04-30 Merck & Co., Inc. Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof
WO2001029027A1 (en) 1999-10-22 2001-04-26 Sankyo Company, Limited 2-alkoxybenzene derivatives
WO2001045707A1 (en) 1999-12-21 2001-06-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001064213A1 (en) 2000-03-02 2001-09-07 Smithkline Beecham Corporation Compounds and methods
JP2001278886A (ja) 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd ベンゾオキサジン誘導体及びこれを含有する医薬
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
EP1347982B1 (de) 2000-12-12 2005-11-16 Neurogen Corporation Spiro[isobenzofuran-1,4'-piperidin]-3-one und 3h-spiroisobenzofuran-1,4'-piperidine
CA2438272A1 (en) 2001-03-02 2002-10-10 John Macor Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
JP4489354B2 (ja) 2001-04-18 2010-06-23 ユーロ−セルティーク エス.エイ. スピロインデンおよびスピロインダン化合物類
JP2002316987A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd 2−アルコキシベンゼン誘導体を含有する医薬
WO2002094825A1 (en) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
HUP0401108A2 (hu) 2001-08-07 2004-09-28 Banyu Pharmaceutical Co., Ltd. Spirovegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2003037271A2 (en) 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
MXPA04005988A (es) * 2001-12-19 2004-09-27 Lundbeck & Co As H 3,4-dihidro-1h-isoquinolin-2-il-derivados.
BR0307268A (pt) 2002-01-28 2004-12-14 Pfizer Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1
WO2003095427A1 (en) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Spiro-ring compound
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
RS52552B (sr) 2002-06-05 2013-04-30 Bristol-Myers Squibb Company Antagonisti, peptidnog receptora koji je u vezi sa kalcitoninskim genom
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
UA77814C2 (en) 2002-07-03 2007-01-15 Lundbeck & Co As H Spirocyclic piperidines as antagonists of mch1 and use thereof
KR101025633B1 (ko) 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
US7045527B2 (en) 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
DE60328035D1 (de) 2002-11-29 2009-07-30 Banyu Pharma Co Ltd Neue azolderivate
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2004222336B2 (en) 2003-03-18 2010-06-03 Merck Sharp & Dohme Corp. Amino cyclobutylamide modulators of chemokine receptor activity
CN1768041A (zh) 2003-04-04 2006-05-03 麦克公司 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物
CN1297557C (zh) 2003-04-10 2007-01-31 上海药明康德新药开发有限公司 螺环类模板化合物的制备
MXPA06001738A (es) * 2003-08-15 2006-05-12 Lundbeck & Co As H Derivados de ciclopropilo como antagonistas del receptor nk3.
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
JP2007516298A (ja) * 2003-12-23 2007-06-21 アリーナ ファーマシューティカルズ, インコーポレイテッド 新規なスピロインドリンまたはスピロイソキノリン化合物、それらの使用方法および組成物
RU2006132465A (ru) 2004-02-10 2008-03-20 Ф.Хоффманн-Ля Рош Аг (Ch) Модуляторы хемокинового рецептора ccr5
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
WO2005097788A2 (en) 2004-04-02 2005-10-20 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
KR20070034524A (ko) 2004-05-28 2007-03-28 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조정자
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
EP2374455A3 (de) * 2004-08-19 2012-03-28 Vertex Pharmaceuticals Incorporated Modulatoren von muskarinischen Rezeptoren
AU2006330866A1 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
PE20090223A1 (es) * 2007-05-04 2009-03-08 Wyeth Corp Compuestos triciclicos como inhibidores de metaloproteinasas matriciales

Also Published As

Publication number Publication date
WO2007100670A1 (en) 2007-09-07
NZ570497A (en) 2011-09-30
KR20080098070A (ko) 2008-11-06
RU2008137583A (ru) 2010-03-27
EP1987034A1 (de) 2008-11-05
US20090227614A1 (en) 2009-09-10
AU2007221220A1 (en) 2007-09-07
JP2009527569A (ja) 2009-07-30
EP1987034B1 (de) 2011-07-20
IL193479A0 (en) 2009-05-04
ATE517106T1 (de) 2011-08-15
US8263605B2 (en) 2012-09-11
CA2642649A1 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
NO20084007L (no) Spirokondenserte piperidiner som modulatorer av muskarinreseptorer
NO20083011L (no) Modulatorer av muskarine receptorer
ATE469895T1 (de) Cgrp-rezeptorantagonisten
NO20071272L (no) Modulatorer av muskarine reseptorer.
ATE522518T1 (de) Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20085029L (no) Substituerte pyridylamidforbindelser som modulatorer av histamin H3 reseptoren
MA32508B1 (fr) Composes organiques
DE502006006854D1 (de) Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika
WO2007106236A3 (en) Pyrrolo-pyridine kinase modulators
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
WO2008021375A3 (en) Modulators of muscarinic receptors
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20084006L (no) Modulatorer av muskarinreseptorer
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE553104T1 (de) Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
NO20082285L (no) 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer
WO2006105035A3 (en) Muscarinic modulators
UY28538A1 (es) Derivados de fenil-piperazina como moduladores de receptores muscarínicos
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application